公开(公告)号：US20240076287A1

公开(公告)日：2024-03-07

申请号：US18268959

申请日：2021-12-21

Applicant: PFIZER INC.

Inventor： Fengjuan CAO ,  Kevin Francis DEBOYACE ,  Michael HEBERLEIN

IPC: C07D403/12

CPC classification number: C07D403/12

Abstract: The invention relates to solid forms of (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}amino)-1H-pyrazol-5-yl]cyclopentyl propan-2-ylcarbamate, to pharmaceutical compositions comprising such solid forms, and to use of such solid forms and pharmaceutical compositions for the treatment of cancer.

公开(公告)号：US20230167080A1

公开(公告)日：2023-06-01

申请号：US18060027

申请日：2022-11-30

Applicant: Pfizer Inc.

Inventor： Leanne Marie BUZON ,  Kimberly O'Keefe CAMERON ,  Kevin Francis DEBOYACE ,  Kevin James FILIPSKI ,  David Andrew GRIFFITH ,  Bethany Lyn KORMOS ,  Shenping LIU ,  Luis Angel MARTINEZ ALSINA ,  Matthew Richard REESE ,  Rachel Jane ROTH FLACH ,  Yuan ZHANG

IPC: C07D333/68 ,  A61P3/04 ,  A61P9/00

CPC classification number: C07D333/68 ,  A61P3/04 ,  A61P9/00 ,  C07B2200/13

Abstract: Described herein are compounds of Formula I,




wherein the variables are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, diabetes, kidney disease, NASH and heart failure.